Moderna

Have you ever wondered what happens when you're infected with a virus like the #flu, or SARS-CoV-2? How does it multiply and spread in your body?    Watch this video to learn how your own cellular machinery fuels the spread of viruses.    You can also head to Module 1 on our free 'mRNAs as Medicines' Coursera course to find out more about how viruses spread: https://lnkd.in/dCtbvvDD #mRNA101

We announced today that the Australian Therapeutic Goods Administration has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.   Read more: https://lnkd.in/eAi8r5ZP

It was a pleasure to welcome Laurent Muschel and his team from the European Commission’s Health Emergency Preparedness and Response Authority (HERA) to Madrid.   We were proud to showcase how Moderna’s manufacturing capabilities — including our partnership with Rovi and our Center of Analytical Excellence — contribute to Europe’s health security.   We have a full end-to-end manufacturing footprint in the European Union, one of our largest outside of the U.S. With a global supply chain, strong R&D focus, and pandemic-hardened contingency plans, we’re prepared to respond to future health threats efficiently and at scale.   #mRNA #HealthSecurity #HERA #PublicHealth #Manufacturing #Madrid

For Monika Kowalska, joining Moderna meant the chance to build something new and make an impact. From ensuring the accuracy of safety data to shaping a growing team, she’s driven by the opportunity to improve how things work.    💡 “Being a changemaker means seeing gaps, asking ‘why,’ reflecting, and figuring out how to make things better,” Monika shares.    Read more about Monika’s journey: https://lnkd.in/eSdbi-gA

This Women’s History Month, our Women’s ERG, WISDM, hosted a career panel featuring senior leaders in our research organization, including Rose Loughlin, EVP, Research, to discuss perseverance, discovery and success from the bench to the office. WISDM plays a key role in fostering career development and leadership opportunities for women at Moderna, creating spaces for learning, connection and growth. Join us in celebrating the women shaping the future of science and beyond. Tag a mentor or ally who has made a difference in your career! #WomensHistoryMonth #WomenInSTEM

In 2024, we navigated a rapidly evolving healthcare ecosystem while making significant progress across our pipeline. With two approved mRNA medicines, a deep late-stage portfolio and cutting-edge digital innovations, we remain focused on delivering impact for patients. Through it all, our people—driven by a shared commitment to science and to each other—continued to push the boundaries of what’s possible.     Read our 2024 Annual Report to learn more: https://lnkd.in/eNASj4Vh

At #SXSW, an important conversation took the stage: how can companies, brands and the medical community bridge the growing communication gap between science and the public? In a world of information overload, making facts clear, engaging and trustworthy is more important than ever. Catch the panel replay and read more here: https://lnkd.in/eWh_6pDt #SXSW2025

We’re thrilled to share that our Chief Brand Officer, Kate Cronin, will be speaking on a panel at SXSW! 🗣 Panel: Crisis to Credibility: Restoring Trust in Modern Science 📅 Date and time: March 7, 2025; 2:30-3:30 p.m. CT 📍 Location: JW Marriott, Salon BC In an age of rapid innovation, the gap between #science and the public has never been more critical to bridge. Kate will join an insightful discussion alongside Dr. Ugo Iroku, Co-Founder, Association of Black Gastroenterologists and Hepatologists and Jonathan Isaacs, Global Chief Creative Officer, Antidote to explore how companies, brands and the medical community can simplify complex science, combat misinformation and build trust. If you are headed to Austin, add the panel to your schedule here: https://lnkd.in/enRyxWSe. #SXSW #ScienceCommunication #TrustInScience

We announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted authorization for our respiratory syncytial virus (RSV) vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults 60 years of age and older. Read more: https://lnkd.in/eTrVFkzV.

For Michelle Patel, joining Moderna was about taking the next step in her #career and finding the right place to drive meaningful change in medicine. It takes urgency, focus and the right team to transform #innovation into life-changing treatments. 💡 “I wanted to be at the precipice of changing the way we think about treating cancers, rare diseases and beyond,” Michelle shares. Read more about Michelle’s role and the mission that is clear to her at Moderna: advance science, embrace risk and push medicine forward for patients who need it most: https://lnkd.in/epWxceDd.